BPI-1178 plus osimertinib for EGFR-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (BPI-1178) combined with osimertinib for advanced lung cancer with EGFR mutations. It’s for people whose cancer has progressed after prior treatment with a third-generation EGFR targeted therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (mainly adenocarcinoma) with an EGFR mutation.
- You have already been treated with a third-generation EGFR targeted drug (like osimertinib) and it stopped working.
- You are 18 or older, able to swallow pills, and have good organ function (kidneys, liver, bone marrow, heart).
- You have not been treated with a CDK4/6 inhibitor before.
- Brain metastases are okay if they are not causing symptoms or are stable after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests how safe and effective repotrectinib plus osimertinib are for people with advanced or metastatic non-squamous lung cancer with specific EGFR mutations. It may help shrink tumors when surgery or radiation can’t cure the cancer, including in some cases after osimertinib or other EGFR pills.
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial tests a new drug (BL-B01D1) combined with osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and who have not had any previous treatment. The goal is to see if the combination works better than standard care.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.